Happy Thanksgiving! Save 50% on Your MarketBeat All Access Subscription.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Walmart shooter left 'death note,' bought gun day of killing
THE BEST BLACK FRIDAY DEAL YET (Ad)
MarketBeat: Week in Review 11/21 - 11/25
See the World with Dollar Flight Club's Lowest Price for Black Friday Weekend
See how to make money instead of spending it on Black Friday with this offer (Ad)
Arrival, Coupa Software rise; Apple, Activision fall
Inflation hovers over shoppers seeking deals on Black Friday
See how to make money instead of spending it on Black Friday with this offer (Ad)
Mexico's domestic airline industry in shambles
Macao awards casino licenses to MGM, Sands, Wynn, 3 others
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Walmart shooter left 'death note,' bought gun day of killing
THE BEST BLACK FRIDAY DEAL YET (Ad)
MarketBeat: Week in Review 11/21 - 11/25
See the World with Dollar Flight Club's Lowest Price for Black Friday Weekend
See how to make money instead of spending it on Black Friday with this offer (Ad)
Arrival, Coupa Software rise; Apple, Activision fall
Inflation hovers over shoppers seeking deals on Black Friday
See how to make money instead of spending it on Black Friday with this offer (Ad)
Mexico's domestic airline industry in shambles
Macao awards casino licenses to MGM, Sands, Wynn, 3 others
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Walmart shooter left 'death note,' bought gun day of killing
THE BEST BLACK FRIDAY DEAL YET (Ad)
MarketBeat: Week in Review 11/21 - 11/25
See the World with Dollar Flight Club's Lowest Price for Black Friday Weekend
See how to make money instead of spending it on Black Friday with this offer (Ad)
Arrival, Coupa Software rise; Apple, Activision fall
Inflation hovers over shoppers seeking deals on Black Friday
See how to make money instead of spending it on Black Friday with this offer (Ad)
Mexico's domestic airline industry in shambles
Macao awards casino licenses to MGM, Sands, Wynn, 3 others
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Walmart shooter left 'death note,' bought gun day of killing
THE BEST BLACK FRIDAY DEAL YET (Ad)
MarketBeat: Week in Review 11/21 - 11/25
See the World with Dollar Flight Club's Lowest Price for Black Friday Weekend
See how to make money instead of spending it on Black Friday with this offer (Ad)
Arrival, Coupa Software rise; Apple, Activision fall
Inflation hovers over shoppers seeking deals on Black Friday
See how to make money instead of spending it on Black Friday with this offer (Ad)
Mexico's domestic airline industry in shambles
Macao awards casino licenses to MGM, Sands, Wynn, 3 others
NASDAQ:CTXR

Citius Pharmaceuticals - CTXR Price Target & Analyst Ratings

$1.19
+0.03 (+2.59%)
(As of 11/25/2022 12:00 AM ET)
Add
Compare
Today's Range
$1.13
$1.19
50-Day Range
$1.02
$1.28
52-Week Range
$0.83
$2.01
Volume
155,342 shs
Average Volume
465,936 shs
Market Capitalization
$173.89 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.00

Citius Pharmaceuticals Consensus Rating and Price Target (2022)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Buy
Based on 2 Analyst Ratings

Consensus Analyst Price Target

$5.00
320.17% Upside
High Prediction$6.00
Average Prediction$5.00
Low Prediction$4.00
TypeCurrent
11/26/21 to 11/26/22
1 Month Ago
10/27/21 to 10/27/22
3 Months Ago
8/28/21 to 8/28/22
1 Year Ago
11/26/20 to 11/26/21
Consensus Rating
Buy
Buy
Buy
Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
2 Buy rating(s)
2 Buy rating(s)
2 Buy rating(s)
2 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$5.00$5.00$5.00$6.00
Predicted Upside320.17% Upside224.15% Upside224.15% Upside170.27% Upside
Get Citius Pharmaceuticals Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for CTXR and its competitors with MarketBeat's FREE daily newsletter.


CTXR Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

CTXR Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Citius Pharmaceuticals Stock vs. The Competition

TypeCitius PharmaceuticalsMedical CompaniesS&P 500
Consensus Rating Score
3.00
2.66
2.48
Consensus RatingBuyBuyHold
Predicted Upside320.17% Upside763.33% Upside12.74% Upside
News Sentiment RatingPositive News
Positive News
Neutral News
MarketBeat
Community Rating
Outperform Votes
202
61.59%
Underperform Votes
126
38.41%
Avg. Outperform Votes
164
66.40%
Avg. Underperform Votes
83
33.60%
Avg. Outperform Votes
853
68.19%
Avg. Underperform Votes
398
31.81%

Historical Target Prices and Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
2/11/2022Maxim Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Michael Okunewitch
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$4.00+164.90%
1/18/2022HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy$4.00 ➝ $6.00+280.95%
2/25/2021Dawson James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
J. Kolbert
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy$6.00+170.27%
(Data available from 11/26/2017 forward. View 10+ years of historical ratings with our analyst ratings screener.)












CTXR Price Target - Frequently Asked Questions

What is Citius Pharmaceuticals's consensus rating and price target?

According to the issued ratings of 2 analysts in the last year, the consensus rating for Citius Pharmaceuticals stock is Buy based on the current 2 buy ratings for CTXR. The average twelve-month price prediction for Citius Pharmaceuticals is $5.00 with a high price target of $6.00 and a low price target of $4.00. Learn more on CTXR's analyst rating history.

Do Wall Street analysts like Citius Pharmaceuticals more than its competitors?

Analysts like Citius Pharmaceuticals more than other Medical companies. The consensus rating score for Citius Pharmaceuticals is 3.00 while the average consensus rating score for medical companies is 2.66. Learn more on how CTXR compares to other companies.

Do MarketBeat users like Citius Pharmaceuticals more than its competitors?

MarketBeat users like Citius Pharmaceuticals less than other Medical companies. 61.59% of MarketBeat users gave Citius Pharmaceuticals an outperform vote while medical companies recieve an average of 66.40% outperform votes by MarketBeat users.

Does Citius Pharmaceuticals's stock price have much upside?

According to analysts, Citius Pharmaceuticals's stock has a predicted upside of 224.15% based on their 12-month price targets.


Stock Ratings Reports and Tools

This page (NASDAQ:CTXR) was last updated on 11/26/2022 by MarketBeat.com Staff